Clinical outcomes of neoadjuvant dual HER2 blockade with pertuzumab/Sigrima and trastuzumab/Vivitra biosimilars: real-world evidence in HER2-positive breast cancer in India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260973Keywords:
Biosimilars, HER2-positive breast cancer, India, Neoadjuvant therapy, Pathological complete response, Real-world evidenceAbstract
Background: HER2-positive breast cancer is an aggressive subtype with a high risk of recurrence. Neoadjuvant chemotherapy (NACT) combined with dual HER2 blockade improves pathological complete response (pCR) rates in clinical trials; however, real-world evidence on biosimilars Sigrima™ and Vivitra™ in India remains limited.
Methods: This retrospective study analysed 571 HER2-positive breast cancer patients enrolled in the ANAYA Care programme. All patients received dual HER2 blockade with Sigrima™ (petuzumab biosimilar) and Vivitra™ (trastuzumab biosimilar), with 495 undergoing NACT. Data on demographics, disease stage, treatment setting, financial assistance, pCR outcomes, and adverse events were collected. pCR was evaluable in 242 patients.
Results: Most patients were aged 46-60 years, with stage II disease being most common, followed by stage III and stage I. The majority were treated in private hospitals, with additional representation from government and trust centres. Financial assistance supported chemotherapy access in 194 patients. Among evaluable patients, 182 achieved pCR, yielding a rate of 75.2%. Treatment was well tolerated, with ~90% reporting no adverse events. Observed toxicities were primarily mild to moderate, including nausea, fatigue, stomatitis, cytopenias, and liver enzyme abnormalities; serious events were rare.
Conclusions: Dual HER2 blockade with Sigrima™ and Vivitra™ demonstrated high efficacy and favourable tolerability in this real-world Indian cohort. These findings support their use as a practical and effective neoadjuvant treatment option in routine clinical practice.
Metrics
References
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. DOI: https://doi.org/10.1126/science.3798106
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA): overall survival results. N Engl J Med. 2015;372(8):724-34. DOI: https://doi.org/10.1056/NEJMoa1413513
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2024. National Comprehensive Cancer Network. 2024.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer. Lancet. 2014;384(9938):164-72. DOI: https://doi.org/10.1016/S0140-6736(13)62422-8
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (NeoSphere). Lancet Oncol. 2012;13(1):25-32. DOI: https://doi.org/10.1016/S1470-2045(11)70336-9
van Ramshorst MS, van der Voort A, van Werkhoven E, Mandjes IA, Kemper I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in HER2-positive breast cancer (TRAIN-2). Lancet Oncol. 2018;19(12):1630-40. DOI: https://doi.org/10.1016/S1470-2045(18)30570-9
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab emtansine vs trastuzumab plus chemotherapy (KRISTINE). Lancet Oncol. 2018;19(1):115-26. DOI: https://doi.org/10.1016/S1470-2045(17)30716-7
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: final OS analysis of CLEOPATRA. Lancet Oncol. 2020;21(4):519-30. DOI: https://doi.org/10.1016/S1470-2045(19)30863-0
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Real-world clinical outcomes with pertuzumab-based therapy. Ann Oncol. 2019;30(5):646-53.
Ghosh J, Gupta S, Desai S, Sengar M, Badwe R. Breast cancer care in India: challenges and opportunities. Lancet Oncol. 2021;22(3):e123-31.
Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for biosimilars in oncology: clinical evidence for trastuzumab biosimilars. ESMO Open. 2018;3(5):e000329.
Bakshi N, Bishnoi R, Sharma A, Jain R. Cost-effectiveness and accessibility impact of biosimilars in oncology in India. JCO Glob Oncol. 2022;8:e2100325.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer (APHINITY): a randomised phase 3 trial. N Engl J Med. 2017;377(2):122-31. DOI: https://doi.org/10.1056/NEJMoa1703643
National Cancer Grid (India). Breast Cancer Management Guidelines. Tata Memorial Centre; 2023.
Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Clinical profile and outcomes of breast cancer patients at Tata Memorial Centre: real-world insights. Indian J Med Paediatr Oncol. 2014;35(3):222-8.
Deo SVS, Mohanti BK, Shukla NK, Raina V, Sharma DN, Thulkar S. Clinical presentation, treatment patterns, and outcomes of breast cancer patients in a tertiary care centre in India (AIIMS experience). Indian J Cancer. 2015;52(1):114-9.
Nathiya K, Pugazhenthi V, Ramesh RP. Impact of the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS) on healthcare accessibility and financial risk protection among low-income households in Tamil Nadu. Int J Manag. 2025;16(6):277-90. DOI: https://doi.org/10.34218/IJM_16_06_018
Doval DC, Radhakrishna S, Tripathi R, Kashinath RI, Talwar V, Batra U, et al. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery. Sci Rep. 2020;10(1):5886. DOI: https://doi.org/10.1038/s41598-020-62618-3
Downloads
Published
How to Cite
Issue
Section
